• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    D

    Dexcom

    企业
    288论文总数
    4,781引用总数

    DexCom, Inc. is a company that develops, manufactures, produce, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona and Batu Kawan in Malaysia.

    论文量&引用量时间轴

    机构学者

    论文(288)

    年份
    起
    –
    止
    排序
    1Safety Generalization under Distribution Shift in Safe Reinforcement Learning: A Diabetes Testbed
    Minjae Kwon,Josephine Lamp,Lu Feng

    Safe Reinforcement Learning (RL) algorithms are typically evaluated under fixed training conditions. We investigate whether training-time safety guarantees transfer to deployment under distribution shift, using diabetes management as a safety-critical testbed. We benchmark safe RL algorithms on a unified clinical simulator and reveal a safety generalization gap: policies satisfying constraints during training frequently violate safety requirements on unseen patients. We demonstrate that test-time shielding, which filters unsafe actions using learned dynamics models, effectively restores safety across algorithms and patient populations. Across eight safe RL algorithms, three diabetes types, and three age groups, shielding achieves Time-in-Range gains of 13-14\% for strong baselines such as PPO-Lag and CPO while reducing clinical risk index and glucose variability. Our simulator and benchmark provide a platform for studying safety under distribution shift in safety-critical control domains.

    2026ICML 2026(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2Feasibility and Benefits of Continuous Glucose Monitoring for Type 1 Diabetes in Rwanda: A Real-World 12-Month Continuation Phase.
    Sandhya Narayanan, Jason Baker, John B Welsh,Giacomo Cappon, Jean Claude Habineza, Simon P Niyonsenga

    AIMS:Continuous glucose monitoring (CGM) remains underutilized in low- and middle-income countries (LMICs). We extend earlier observations on the feasibility and impact of CGM among people living with type 1 diabetes (T1D) in Rwanda in a real-world continuation phase study. METHODS:This was a 1-year continuation phase of a single-arm, mixed-methods, prospective observational study conducted in Kigali, Rwanda, from August 2022 to September 2024. Completers of the 12-month Phase I were transitioned to a current-generation CGM device and, in months 19-24, reduced frequency of clinic visits reflecting routine care. The primary outcomes were change in haemoglobin A1c (HbA1c) and the CGM-based metrics time in range (TIR, 3.9-10 mmol/L), and time below range (TBR, <3.9 mmol/L). Secondary outcomes included self-reported hospitalizations, incidences of severe hypoglycaemia and diabetic ketoacidosis, as well as diabetes-related questionnaire results. RESULTS:At the end of Phase I, 40 of the original 50 participants entered Phase II with mean HbA1c, TIR and TBR of 44 mmol/mol (6.2%), 44.9% and 5.6%, respectively, all metrics being significantly different from study start. These did not change significantly by the end of the study (48 mmol/mol [6.6%], 46.5% and 7.9%, respectively). No hospitalizations, three episodes of severe hypoglycaemia and two episodes of diabetic ketoacidosis were reported. Most respondents were satisfied with the device, used it consistently and trusted the values provided. CONCLUSIONS:CGM-related improvements in HbA1c and TIR among Rwandans living with T1D were maintained for at least 24 months. CGM should be considered as an important tool to improve diabetes self-management in LMICs.

    2026Diabetic medicine a journal of the British Diabetic Association(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Association of Continuous Glucose Monitoring Metrics with Incident Diabetic Retinopathy: A Real-World Long-Term Study.
    Tomoki Okuno, Sharon A Macwan, Gregory J Norman,Donald R Miller,Peter D Reaven, Jin J Zhou

    We analyzed data from 2253 veterans with type 1 (34%) or type 2 (66%) diabetes who initiated Dexcom continuous glucose monitoring (CGM) between 2015 and 2022, all with ≥10 days of data over a 6-month landmark period. CGM data were merged with electronic health records (EHR). Diabetic retinopathy (DR) was defined from EHR diagnoses. Incident DR was assessed up to 4 years from CGM initiation. Cox models evaluated associations between CGM metrics (mean glucose [MG], time in range [TIR], time above range [TAR], glycemia risk index [GRI], coefficient of variation, and week-to-week average real variability [ARV]) and DR. There were 99 incident DR events. In separate multivariable models, higher MG, TAR, GRI, and ARV, and lower TIR were associated with DR risk; these associations (except ARV) remained significant after landmark HbA1c adjustment and were stronger than for landmark HbA1c itself, suggesting that CGM metrics provide more informative risk stratification than HbA1c alone.

    2026Diabetes technology & therapeutics(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes.
    Halis Kaan Akturk, Kagan Ege Karakus, Boyang Chen,Tomas C Walker

    BACKGROUND:Rebound hyperglycemia (RHyper), rebound hypoglycemia (RHypo), extended hyperglycemia (EHyper), and extended hypoglycemia (EHypo) are newly defined continuous glucose monitoring (CGM) metrics. Here, we investigated the characteristics of these new metrics and the relationship between new CGM metrics and standard metrics. MATERIALS AND METHODS:In this retrospective cohort study, 30,000 CGM users with at least 90 days of CGM data were randomly selected from Dexcom Clarity database. Standard and new CGM metrics were calculated for each user. Four different cutoffs were used to define RHyper and RHypo, and two cutoffs were used to define EHyper and EHypo events. The number of RHyper, RHypo, EHyper, and EHypo events per week, mean duration of events, and mean area under the curve of events were calculated. For rebound events, the rate of change (ROC) was calculated. Pearson correlation and simple linear regression were used to analyze the data. RESULTS:Mean time in 70-180 mg/dL was 61.8 ± 20.7%, mean glucose was 173 ± 37.1 mg/dL, and coefficient of variation (CV) was 32.1 ± 7.2%. RHyper, RHypo, and EHyper were more frequent during daytime and increased throughout the day. EHypo mostly occurred during nighttime. CV correlated strongly with RHyper (70-180 mg/dL) events/week (r = 0.67) and RHypo (180 to 70 mg/dL) events/week (r = 0.64). Time in range had the strongest correlation with EHyper events/week (r = -0.88) among new metrics. RHyper events and RHypo events were strongly correlated with each other (r = 0.92). RHyper and RHypo ROC have a stronger correlation with CV than the correlation between CV and time below range (TBR) metrics. CONCLUSIONS:For rebound and extended metrics, the most important metric was the number of events/week. RHyper and RHypo had a stronger correlation with CV and hypoglycemia metrics (TBR) than the correlation between CV and TBR. Thus, rebound events have the potential to detect hypoglycemia events caused by glycemic variability.

    2026Diabetes technology & therapeutics(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5IMPROVEMENT IN GLYCEMIC CONTROL WITH REAL-TIME CGM USE IN ADULTS AND CHILDREN WITH TYPE 1 DIABETES IN THE ARAB GULF REGION
    Abdullah Alguwaihes, Alexander Carite, Corbin Griffen, Hossam Yousri, Jennifer Layne
    2026DIABETES TECHNOLOGY & THERAPEUTICS(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 288 篇论文

    合作机构(100)

    弗吉尼亚大学合作论文 15
    华盛顿大学合作论文 11
    斯坦福大学合作论文 9
    科罗拉多州立大学合作论文 8
    加利福尼亚大学圣地亚哥分校合作论文 7
    马萨诸塞大学合作论文 7
    Diablo Clinical Research合作论文 6
    帝国理工学院合作论文 5
    帕多瓦大学合作论文 5
    Rocky Mountain Diabetes and Osteoporosis Center合作论文 5

    机构统计